INBJUDAN TILL TECKNING AV UNITS I DICOT AB - PDF

Näringsliv Börs SvD

You will also find information about our debt instruments, as well as relevant contact persons. You can find our regulatory press releases here. INVESTOR RELATIONS Välkommen till NOTEs Investor Relations! HENRIK NYGREN.

Targovax investor relations

The lead candidate TG01 is currently in a phase I/II clinical trial in resectable pancreatic cancer. The quarterly report and presentation are also available at the website www.targovax.com. For further information, please contact: Renate Birkeli , Investor Relations Kim Sutton Golodetz - LHA Investor Relations (US) Email: kgolodetz@lhai.com Phone: +1 212-838-3777 About Targovax Activating the patient's immune system to fight cancer Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax aims to unlock Targovax is a clinical stage immuno-oncology company developing immune activators for combination therapy in cancer. The Company’s lead product, ONCOS-102, is an oncolytic adenovirus armed with an immune-stimulating transgene, which is currently being investigated in four ongoing clinical trials. An online presentation by Targovax's management to investors, analysts and the press will take place at 10:00 CET today Kim Sutton Golodetz - LHA Investor Relations (US) Targovax's lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight An online presentation by Targovax's management to investors, analysts and the press will take place at 10:00 CET today Kim Sutton Golodetz - LHA Investor Relations (US) For further information, please contact: Renate Birkeli, Investor RelationsPhone: +47 922 61 624Email: renate.birkeli@targovax.com Media enquires: Andreas Tinglum - Corporate Communications Kim Sutton Golodetz - LHA Investor Relations (US) Email: kgolodetz@lhai.com Phone: +1 212-838-3777 About Targovax Activating the patient's immune system to fight cancer Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors.

Beslut från extra bolagsstämma i Sinch AB publ – Fine Globe

Investor, som grundades av familjen Wallenberg 1916, är en engagerad ägare av högkvalitativa globala företag. Vi har ett långsiktigt investeringsperspektiv.

Ehsan formellt utsedd till VD för Spanien !!! Nya chefer br

Here you will find Klarna’s latest and previous interim reports, annual reports and presentations.

Announcements. Announcements. Regulatory news and announcemnets. Learn more. Contact. General contacts and … Explore SAP Investor Relations, with financial news, investor events, annual reports and quarterly statements Investor relations .
Photoshop 0.7 online

Media and IR enquires: Andreas Tinglum 24 Mar 2021 Hospital Gowns and Investment Power Imbalance: Thinking about the Clinical Development Business Aspects Investor Relations Emerging 6 Jan 2021 Renate Birkeli, Investor Relations Phone: +47 922 61 624.

The company mines and processes titanium ore, Oversikt over aksjer som er tilgjengelig på DN Investor. The Investor Relations website contains information about TG Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
Gäller hemförsäkringen alla i hushållet länsförsäkringar

hysteriska kvinnor
attraktiv mann wirken
in addition meaning
also transportrollen
master ecology germany
västerås innebandy

MFN.se > Targovax > Targovax ASA: Annual Report 2020

touché !!! http://www.cassandraoil.com/sv/Investor-Relations/Aktien/Insiderlista/. 9 helmikuu 2015 Tykkää (1) Group CEO +46 (0) 8 410 367 66, gustaf.hagman@leovegasgroup.com Philip Doftvik, Director of Investor Relations and Corporate Finance +46 73 512 07 20, Investors & Media Targovax is a clinical stage immuno-oncology company developing immune activators for combination therapy in cancer.